Status:

UNKNOWN

PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT

Lead Sponsor:

Ruijin Hospital

Conditions:

Lymphoma, Large B-Cell, Diffuse

Transplantation

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B...

Detailed Description

This is a multicenter, randomized controlled, prospective clinical trial. The objective is to investigate the efficacy and safety of Tislelizumab maintenance therapy in newly diagnosed diffuse large B...

Eligibility Criteria

Inclusion

  • Male and female, aged 18-65;
  • newly-diagnosed high risk (aaipi 2-3 and aaipi 1 with large mass) DLBCL patients after autologous stem cell transplantation;
  • Laboratory tests (blood tests, liver and renal function) meet the following requirements:
  • Blood tests: white blood cell count ≥ 3.0 × 109 / L, absolute neutrophil count ≥ 1.5 × 109 / L, hemoglobin ≥ 90g / L, platelet ≥ 75 × 109 / L
  • Liver function: transaminase ≤ 2.5 × upper limit of normal value, bilirubin ≤ 1.5 × upper limit of normal value;
  • Renal function: serum creatinine 44-133 mmol / L;
  • The score of ECOG was 0-2;
  • The subject or his legal representative must provide written informed consent before the special examination or procedure of the study.

Exclusion

  • Pregnant or lactating women;
  • Severe complications or infection;
  • Lymphoma involving central nervous system;
  • Participate in other clinical trials at the same time;
  • According to the judgment of the researcher, the patients who are not suitable for this study were selected.

Key Trial Info

Start Date :

July 9 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2024

Estimated Enrollment :

94 Patients enrolled

Trial Details

Trial ID

NCT04789434

Start Date

July 9 2021

End Date

July 1 2024

Last Update

November 22 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ruijin Hospital

Shanghai, Shanghai Municipality, China, 200020